Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC

Jyoti Arora, Sabarish Ayyappan, Chaobo Yin, Brian J. Smith, Caitlin D. Lemke-Miltner, Zhaoming Wang, Umar Farooq, George J. Weiner

Blood (2024) 143 (18): 1816–1824.

https://doi.org/10.1182/blood.2023023370

Published: 2024

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Blood (2023) 142 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2023-180743

Published: 2023

Journal Articles

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 436.

https://doi.org/10.1182/blood-2023-179818

Published: 2023

Journal Articles

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Krish Patel, Youngil Koh, Sabarish Ayyappan, Yasmin Karimi, Izidore S. Lossos, Akil Merchant, Phuong Lee, Jianhua Jin, Raphael Clynes, Jitendra Kanodia, Michael T. Chiarella, Steve Kye, Jean-Marie Michot

Blood (2022) 140 (Supplement 1): 12066–12067.

https://doi.org/10.1182/blood-2022-158042

Published: 2022

Journal Articles

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Blood (2022) 140 (Supplement 1): 9390–9392.

https://doi.org/10.1182/blood-2022-159001

Published: 2022

Journal Articles

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Blood (2022) 140 (Supplement 1): 6517–6519.

https://doi.org/10.1182/blood-2022-165419

Published: 2022

Journal Articles

Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry

David A. Bond, Jason T. Romancik, Jeffrey M. Switchenko, Brielle Berkowitz, Jonathan R Day, Umar Farooq, Sabarish Ayyappan, Katelin Baird, Michelle L. Churchman, Andrew M. Evens, Bijal D. Shah, Craig A. Portell, Kami J. Maddocks, Brian K. Link, Jonathon B. Cohen, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 6509–6511.

https://doi.org/10.1182/blood-2022-160306

Published: 2022

Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Blood (2022) 140 (Supplement 1): 1070–1071.

https://doi.org/10.1182/blood-2022-158406

Published: 2022

Journal Articles

Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 6489–6491.

https://doi.org/10.1182/blood-2022-167633

Published: 2022

Journal Articles

A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication

Blood (2021) 138 (Supplement 1): 50.

https://doi.org/10.1182/blood-2021-149728

Published: 2021

Journal Articles

Development of a Risk Score for Cardiovascular Events in Anthracycline Treated DLBCL Patients

Akiva Diamond, Sabarish Ayyappan, Shufen Cao, Nour Tashtish, Kirsten M Boughan, Brenda W. Cooper, Pingfu Fu, Paolo F. Caimi

Blood (2021) 138 (Supplement 1): 2536.

https://doi.org/10.1182/blood-2021-153862

Published: 2021

Journal Articles

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Veronika Bachanova, Livia Hegerova, Qing Cao, Murali Janakiram, Joseph Maakaron, Sabarish Ayyappan, Daniel J. Weisdorf, Jaroslav Zak, Umar Farooq, Vaishalee P. Kenkre

Blood (2021) 138 (Supplement 1): 230.

https://doi.org/10.1182/blood-2021-149675

Published: 2021

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Kami J. Maddocks, MD, Farrukh T. Awan, MD MS, Ying Huang, MA, MS, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MD MS, Samantha Jaglowski, MD MPH, Basem M. William, MRCP, MD, Kristie A. Blum, MD, Beth A. Christian, MD

Blood (2018) 132 (Supplement 1): 4185.

https://doi.org/10.1182/blood-2018-99-117172

Published: 2018

Journal Articles

Effect of Histologic Grade on Clinical Outcomes of Follicular Lymphoma: Prolonged Progression Free Survival of Grade 3 Follicular Lymphoma in the Rituximab Era

Suchitra Sundaram, MBBS, Erika Moore, MD, Sabarish Ayyappan, MBBS, Fahrettin Covut, MD, Benjamin Tomlinson, MD, Richard Creger, PhD, Ehsan Malek, MD, Leland Metheny, MD, Brenda W. Cooper, MD, Hillard M Lazarus, MD, Marcos de Lima, MD, Paolo Caimi, MD

Blood (2017) 130 (Supplement 1): 2775.

https://doi.org/10.1182/blood.V130.Suppl_1.2775.2775

Published: 2017

Journal Articles

Central Nervous System Relapse in Diffuse Large B Cell Lymphoma—Predictors at Diagnosis

Sabarish Ayyappan, MBBS, Fahrettin Covut, MD, Dhivya Prabhakar, MD, Vinita Gupta, MD, Ehsan Malek, MD, Leland Metheny, MD, Ben K. Tomlinson, MD, Richard Creger, PhD, Brenda W. Cooper, MD, Hillard M Lazarus, MD, Marcos de Lima, MD, Paolo Caimi, MD

Blood (2017) 130 (Supplement 1): 2842.

https://doi.org/10.1182/blood.V130.Suppl_1.2842.2842

Published: 2017

Journal Articles

Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma. Incidence, Risk Factors and Outcomes

Sabarish Ayyappan, MD, Dhivya Prabhakar, MD, Vinita Gupta, MD, Brenda Cooper, MD, Hillard M. Lazarus, MD, Marcos De Lima, MD, Paolo F. Caimi, MD

Blood (2015) 126 (23): 3968.

https://doi.org/10.1182/blood.V126.23.3968.3968

Published: 2015

Journal Articles

Retrospective Study Of Incidence Of Thromboses In Chinese Versus African Americans With Multiple Myeloma

Radha Raghupathy, MD, Sabarish Ayyappan, MD, Dhivya Prabhakar, MD, Frankie KF Mo, Erica L. Campagnaro, MD, Kenny Ieng Kit Lei, MD, FRCP

Blood (2013) 122 (21): 1121.

https://doi.org/10.1182/blood.V122.21.1121.1121

Published: 2013

Journal Articles

Retrospective Exploratory Study of HIV+ Patients with and without Paraproteinemia for Association with HIV Status, Comorbidities and Development of Hematological Malignancies

Erin Jou, MD, Diwakar Mohan, MD, MPH, Sabarish Ayyappan, MD, Oleg Gligich, MD, Henny Heisler Billett, MD, Anthony T.C. Chan, MD, Radha Raghupathy, MD

Blood (2012) 120 (21): 1827.

https://doi.org/10.1182/blood.V120.21.1827.1827

Published: 2012

NARROW

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication

Development of a Risk Score for Cardiovascular Events in Anthracycline Treated DLBCL Patients

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Effect of Histologic Grade on Clinical Outcomes of Follicular Lymphoma: Prolonged Progression Free Survival of Grade 3 Follicular Lymphoma in the Rituximab Era

Central Nervous System Relapse in Diffuse Large B Cell Lymphoma—Predictors at Diagnosis

Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma. Incidence, Risk Factors and Outcomes

Retrospective Study Of Incidence Of Thromboses In Chinese Versus African Americans With Multiple Myeloma

Retrospective Exploratory Study of HIV+ Patients with and without Paraproteinemia for Association with HIV Status, Comorbidities and Development of Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only